By examining the key indicators between Renalytix and Cigna, you can compare the impact of market volatilities on both companies' stock prices and assess if they can mitigate market risk when combined in one of your portfolios. Pair trading strategies can also be employed, such as matching a long position in Cigna with a short position in Renalytix. For more information, please visit our
pair correlation module.
Now, let's analyze the assets. The asset utilization indicator refers to the revenue generated for every dollar of assets a company currently holds. Renalytix has an asset utilization ratio of 4.7 percent, indicating that the company generates $0.047 for each dollar of assets. An increase in asset utilization suggests that Renalytix AI is becoming more efficient in using each dollar of assets in its daily operations.
Additional examination
Renalytix AI (USA Stocks: RNLX), a company specializing in artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases, presents a potential investment opportunity with its KidneyIntelX diagnostic platform. Despite a net income loss of
49.6M, the company boasts a strong current ratio of 2.48X and a significant working capital of
32.98M. With a market capitalization of
134.6M and a relatively low debt to equity ratio of 0.005%, Renalytix AI demonstrates financial stability. Furthermore, insider ownership stands at 9.09%, indicating a high level of confidence from those intimately familiar with the company's operations. Given these factors, Renalytix AI could be a promising investment, especially if a reconciliation with Cigna Corp materializes.
Investment perspective, in general, refers to a viewpoint or opinion regarding investment opportunity in Renalytix. It encompasses the assessment of an investment's potential risks and rewards, and expectations for its
performance over time. Several factors influence the investment perspective on Renalytix, including investment goals, risk tolerance, time horizon, market conditions, and research and analysis. Investors have varying goals, such as capital preservation, income generation, or long-term growth. Risk tolerance plays a significant role in shaping an investor's perspective, with some being more risk-averse and others willing to take on higher risks for potential returns.
Watch out for price decline
Please consider monitoring Renalytix on a daily basis if you are holding a position in it. Renalytix is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Renalytix stock to be traded above the $1 level to remain listed. If Renalytix stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Renalytix's Liquidity
Renalytix
financial leverage refers to using borrowed capital as a funding source to finance Renalytix AI ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Renalytix financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Renalytix's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Renalytix's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Renalytix's total debt and its cash.
Renalytix Gross Profit
Renalytix Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Renalytix previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Renalytix Gross Profit growth over the last 10 years. Please check Renalytix's
gross profit and other
fundamental indicators for more details.
An Additional Perspective On Renalytix AI
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Revenue Breakdown
Lets now check Renalytix revenue. Based on the latest financial disclosure, Renalytix AI reported 2.97
M of revenue. This is 99.96% lower than that of the Health Care Technology sector and significantly higher than that of the
Health Care industry. The revenue for all United States stocks is 99.97% higher than that of Renalytix.
As for Cigna Corp we see revenue of 180.64
B, which is much higher than that of the Health Care
| RNLX | 2.97 Million | 0.001644 |
| Sector | 0.0 | 0.0 |
| CI | 180.64 Billion | 100.0 |
Renalytix AI (USA Stocks: RNLX), a key player in the Health Information Services industry, has shown potential for a significant reconciliation with Cigna Corp. Despite operating losses of $57.4M and a net income loss of $49.6M, Renalytix AI has demonstrated resilience with a robust book value of 0.386 and a price to book ratio of 3.60X. The company's total assets stand at $63.26M, with working capital at $32.98M and a manageable total debt of $12.71M. Renalytix AI's beta of 2.01 indicates a higher level of volatility compared to the market, but this is balanced by a positive total risk alpha of 0.6713 and a Treynor ratio of 0.2618, suggesting a decent risk-adjusted return. The company's shares have shown stability, with a 52-week high of $3.92 and a 50-day moving average of $2.2626. The company's shares are largely institutionally owned at 8.08%, with insider ownership at 9.09%. Despite a quarterly revenue growth of -0.11, the company has managed to generate a net interest income of $9.6M. With a target price of $5 and potential upside of 9.95, Renalytix AI presents an interesting investment opportunity in the healthcare technology sector. .
Our take on today Renalytix rise
Renalytix AI has shown a significant increase in its current skewness, rising above 3.38. This indicates that the stock is experiencing a considerable deviation from the average return, suggesting a potential surge in positive returns. This asymmetric return distribution could potentially result in higher than anticipated gains for investors. Therefore, based on today's data, we recommend investors to consider investing in Renalytix AI, as the current market dynamics could potentially generate significant returns. Renalytix AI is exhibiting above-average volatility over the chosen time period. Investors should thoroughly analyze Renalytix AI to ensure that their intended
market timing strategies align with their expectations about the company's volatility. Understanding different
market volatility trends often assists investors in timing the market. Proper use of volatility indicators allows traders to assess Renalytix's stock risk against market volatility during both bullish and bearish trends.
The heightened level of volatility that accompanies bear markets can directly affect
Renalytix's stock price, adding stress to investors as they watch the value of their shares decline. This typically compels investors to rebalance their portfolios by purchasing different stocks as prices drop. Despite a modest market slide, Renalytix AI stock has shown impressive resilience, rising over 11 percent. The company, which develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases, has a strong market valuation of
3.19 and a real value of
3.69. The analyst overall consensus is a 'Strong Buy', with three strong buy recommendations. The analyst target price estimated value is 4.5, with a possible upside price of 10.65, indicating significant potential for further growth. Given these factors, and considering the fiscal year end in June, investing in Renalytix AI stock could be a wise decision for those looking to capitalize on the company's upward trajectory. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Aina Ster is a Member of Macroaxis Editorial Board. Aina delivers weekly perspective on ongoing market and economic trends, analysis and tips from predictive analysis to forecasting across various financial instruments.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Aina Ster do not own shares of Renalytix AI. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
